RxDoctor Payments Data

Jennifer Tuck

Psychiatric/Mental Health · Gainesville, FLNPI 1285282962

Payments from drug & device makers

$5,618in general payments, 2019–2025

Across 261 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$742
  • Otsuka America Pharmaceutical, Inc.$585
  • Teva Pharmaceuticals USA, Inc.$527
  • Alkermes, Inc.$234
  • plus $608 from 12 others

What the payments were for

  • Food & beverage$5,56999%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,618 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$4,354
Medicare patients
25
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate28$87,248
AristadaAripiprazole Lauroxil11$38,116
VraylarCariprazine Hcl15$20,768
Quetiapine Fumarate ErQuetiapine Fumarate83$3,870
Aripiprazole53$3,825
Lurasidone Hcl18$2,441
Divalproex Sodium ErDivalproex Sodium35$1,348
Olanzapine77$1,344
Quetiapine Fumarate54$1,231
Benztropine Mesylate44$977
Buspirone Hcl36$762
Mirtazapine38$723
Hydroxyzine Hcl29$719
Haloperidol20$639
Lamotrigine44$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$145$87,24828 claims
Alkermes, Inc.Aristada$234$38,11611 claims
AbbVieVraylar$1,757$20,76815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →